Clinical trials: sponsored by Institut Paoli-Calmettes
Breast Cancer
Utilization of Genomic Signature as Decision-making for Adjuvant Treatment of Breast Cancer
Method: This multicentric prospective cohort is composed of patients with no metastatic breast cancer selected by tumor's genomic analysis and treated by chemotherapy with Anthracycline without Taxanes (6 cycles of FEC 100).
- Trial name
- SA02 (NCT00912080)
- Testing
- genomic signature
- Where
- 4 sites in France
- Volunteers
- 375 people
- Sponsor
- Institut Paoli-Calmettes
Advanced Neoplasm
Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b (" Metronomic Chemotherapy ") for Antiangiogenic and Antivascular Effect. Trial With Pharmacodynamic Study in Adult Advanced Neoplasm
Purpose: This phase I trial estimates the antiangiogenic and antivascular effect of 4 different levels of continuous low doses of the combination of Vinorelbine, Cyclophosphamide and Interferon alpha 2b (" metronomic chemotherapy…
- Trial name
- METRO1 (NCT00908869)
- Testing
- Vinorelbine, Cyclophosphamide and Interferon alpha 2b
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Institut Paoli-Calmettes
Breast Neoplasms, Prostate Cancer
Evaluation of the Cryotherapy in the Prevention of Nails Toxicity Induced by Taxotere® in Breast or Prostate Cancer
Taxotere® can induce nails changes like dyschromia, hematoma, lines of Beau-Reil (signing the stop of the epithelial proliferation), abscess, or pain.
- Conditions
- Breast Neoplasms, Prostate Cancer, Nail Diseases
- Trial name
- CRYO1 (NCT00925418)
- Testing
- Frozen Glove
- Where
- France
- Volunteers
- 168 people
- Sponsor
- Institut Paoli-Calmettes
Sepsis, Septic Shock
Evaluation of Predictive Proteic Profile on Mortality in the Acute Phase of Septic Shock in Cancer Patients
The mortality induced by infections in onco-hematological patients is abnormally high at the acute phase of septic shock. Consequently, it is important to detect the population with a high risk of short term mortality among…
- Conditions
- Sepsis, Septic Shock, Cancer
- Trial name
- PROTEOHSEPS (NCT00930085)
- Testing
- SELDI-TOF MS for plasmatic proteic profile
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Institut Paoli-Calmettes
Chronic Lymphocytic Leukemia
Natural Killer Cells Function in Patients With Chronic Lymphocytic Leukemia
Purpose: The involvement of Natural Killer cells (NK) in the efficiency of the treatment in lymphoma and the beginning of new therapies based on function and activation of NK, justify an improvement of knowledge about the status…
- Trial name
- LLC-NK (NCT00934986)
- Testing
- Surface expression of functional biomarkers of the NK cell
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Institut Paoli-Calmettes
Chronic Myeloproliferative Disorders, Leukemia
Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant using stem cells that closely match the patient's stem cells, helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00806767
- Testing
- therapeutic immune globulin, busulfan, fludarabine phosphate
- Where
- France
- Volunteers
- 82 people
- Sponsor
- Institut Paoli-Calmettes
Multiple Myeloma and Plasma Cell Neoplasm
Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00802568
- Testing
- anti-thymocyte globulin, busulfan, fludarabine phosphate
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Institut Paoli-Calmettes
Leukemia
Natural Killer Cells in Older Patients With Acute Myeloid Leukemia
RATIONALE: Studying natural killer cells in samples of blood from patients with cancer may help doctors find out how these cells are effected by chemotherapy.
- Trial name
- NCT00540956
- Testing
- cytarabine, laboratory biomarker analysis
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Institut Paoli-Calmettes
Leukemia
Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as laromustine, daunorubicin, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00840684
- Testing
- amsacrine, busulfan, cytarabine
- Where
- France
- Volunteers
- 135 people
- Sponsor
- Institut Paoli-Calmettes
Leukemia
Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission
RATIONALE: Vaccines made from dendritic cells may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side effects of vaccine therapy and to see how well it works in…
- Trial name
- NCT00963521
- Testing
- therapeutic autologous dendritic cells
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Institut Paoli-Calmettes
Graft Versus Host Disease, Leukemia
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and cyclophosphamide, together with antithymocyte globulin before a donor stem cell transplant helps stop the growth of cancer and abnormal cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00740467
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Institut Paoli-Calmettes
Pancreatic Cancer
Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00541021
- Testing
- gemcitabine hydrochloride, sorafenib tosylate
- Where
- France
- Volunteers
- 104 people
- Sponsor
- Institut Paoli-Calmettes